$9.35
-0.14-1.48%
Last update: Nov 10, 4:47 PM
Candel Therapeutics Inc
CADLNASDAQ
Candel Therapeutics rose 87.2% from $5.07 to $9.49, ahead of the S&P 500's +10.0%. Its worst day was Feb 20 (−14.2%), and its low came Nov 19 at $4.42.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.21 missed the $-0.17 estimate on $0.00 revenue.
−6.3% · S&P 500 −1.7%
Candel Therapeutics shares rose 11.6%, while the S&P 500 rose 0.2%.
+11.6% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
Candel Therapeutics shares fell 14.2%, while the S&P 500 rose 0.7%.
−14.2%, the year's worst day · S&P 500 +0.7%
EPS of $-0.54 missed the $-0.24 estimate on $0.00 revenue.
−2.4% · S&P 500 −1.5%
Candel Therapeutics shares rose 23.4%, while the S&P 500 rose 1.2%.
+23.4%, the year's best day · S&P 500 +1.2%
Candel Therapeutics shares rose 16.4%, while the S&P 500 fell 0.4%.
+16.4% · S&P 500 −0.4%
EPS of $-0.14 beat the $-0.30 estimate on $0.00 revenue.
−0.3% · S&P 500 +0.8%
EPS of $-0.52 missed the $-0.23 estimate on $0.00 revenue.
+10.5% · S&P 500 +0.7%
Candel Therapeutics closed at its highest level of the year, 171.2% above where the year started.
+3.5% · S&P 500 +0.7%
Where it ended: a close of $9.49 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.31).
Nothing in the past 12 months.
All CADL dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CADL and SPY from Benzinga historical bars. Not investment advice.
